Author

B. Falini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Marra· 2 shared V. Tini· 2 shared A. D. Cabras· 1 shared A. di Napoli· 1 shared A. Gagliardi· 1 shared A. J. M. Ferreri· 1 shared A. Sivacegaram· 1 shared A. Tucci· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Marra

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

B cell receptor silencing reveals the origin of high-grade B cell lymphomas with MYC and BCL2 rearrangements

P. Sindaco, S. Lonardi, G. Varano, I. Pietrini, G. Morello, P. Balzarini, H. Neuman, F. Vit, G. Bertolazzi, H. Arima, M. Chiarini, L. Lorenzi, V. Pellegrini, S. Giampaolo, D. Garzon, , S. Casola

This paper shows that high-grade B cell lymphomas with MYC and BCL2 rearrangements originate from BCR-silenced follicular lymphoma cells that acquire IGL::MYC translocations, leading to resistance to CD79B-targeting therapy.

bioRxiv · Jul 13, 2024Cancer Biology

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML

G. Pianigiani, A. Gagliardi, F. Mezzasoma, F. Rocchio, V. Tini, B. Bigerna, P. Sportoletti, S. Caruso, A. Marra, G. Spinozzi, S. Shacham, Y. Landesman, C. Quintarelli, F. Locatelli, M. P. Martelli, , L. Brunetti

This study shows that prolonged XPO1 inhibition is more effective than intermittent dosing in NPM1-mutated AML by achieving stable HOX downregulation and anti-leukemic activity.

bioRxiv · Dec 11, 2021 · PreprintCancer Biology

The metalloproteinase inhibitor Prinomastat reduces AML growth,prevents stem cell loss and improves chemotherapy effectiveness

C. Pirillo, M. Haltalli, S. Gonzalez Anton, V. Tini, I. Kong, E. Hawkins, B. Falini, A. Marra, D. Duarte, C. Lo Celso

This study shows that prinomastat, an MMP inhibitor, reduces AML growth, prevents stem cell loss, and enhances chemotherapy effectiveness in a mouse model.

bioRxiv · Dec 1, 2020 · PreprintCancer Biology